Back to Stakeholders
Care Delivery & Psychedelic FacilitationClinical Care Delivery OrganizationsHealth Systems & Hospitals
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups
Care Delivery & Psychedelic FacilitationClinical Care Delivery Organizations
Care Delivery & Psychedelic Facilitation
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

Mclean Hospital

United States
4 Trials

Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.

Academic Research

0 papers

Published Papers

0

Trial Involvement

4

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type
Other
HQ
United States
Website
Visit

Sponsored Trials

2
CompletedNA

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

Start Date
Compounds
Ketamine
Unknown statusNA

Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder

Start Date
Compounds
Ketamine

Collaborated Trials

2
Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date
Compounds
Ketamine, Placebo
TerminatedII

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

Start Date
Compounds
MDMA